凱萊英(002821.SZ):擬出資3億元在鎮江設立全資子公司 主營小分子CDMO化學原料及原料藥研發生產
格隆匯 9 月 28日丨凱萊英(002821.SZ)公佈,公司計劃以自有資金3億元人民幣在江蘇省鎮江市設立全資子公司凱萊英制藥(江蘇)有限公司(名稱以工商登記為準,以下簡稱“江蘇凱萊英”),主要從事小分子CDMO化學原料及原料藥的研發生產業務。江蘇凱萊英的設立,將進一步提升凱萊英一站式綜合服務能力,助力公司戰略佈局的實現。
公司於2020年9月28日召開第三屆董事會第四十六次會議審議通過了《關於公司在鎮江投資設立全資子公司的議案》,根據《深圳證券交易所股票上市規則》、《公司章程》及《公司對外投資管理制度》等相關規定,該事項在董事會決策權限內,無需提交公司股東大會審議批准。
本次投資不構成關聯交易,不屬於《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.